Terms: = Germ cell tumor AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Clinical Outcome
35 results:
1. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
[TBL] [Abstract] [Full Text] [Related]
2. ptenP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Suryo Rahmanto A; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Frostvik Stolt M; Tuominen R; Sangfelt O; Pokrovskaja Tamm K; Hansson J; Grandér D; Egyházi Brage S; Johnsson P
Sci Rep; 2021 May; 11(1):11023. PubMed ID: 34040017
[TBL] [Abstract] [Full Text] [Related]
3. Expression of GNAS, TP53, and pten Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Features of Metastatic Testicular Sex Cord Stromal tumors.
Necchi A; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Ross JS; Jacob JM
Eur Urol Focus; 2019 Sep; 5(5):748-755. PubMed ID: 31147264
[TBL] [Abstract] [Full Text] [Related]
5. Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome.
Kenawy N; Kalirai H; Sacco JJ; Lake SL; Heegaard S; Larsen AC; Finger PT; Milman T; Chin K; Mosci C; Lanza F; Moulin A; Schmitt CA; Caujolle JP; Maschi C; Marinkovic M; Taktak AF; Heimann H; Damato BE; Coupland SE
Pigment Cell Melanoma Res; 2019 Jul; 32(4):564-575. PubMed ID: 30672666
[TBL] [Abstract] [Full Text] [Related]
6. Revisiting the clinical and Biologic Relevance of Partial pten Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic value of NUSAP1 in progression and expansion of glioblastoma multiforme.
Qian Z; Li Y; Ma J; Xue Y; Xi Y; Hong L; Dai X; Zhang Y; Ji X; Chen Y; Sheng M; Sheng Y; Yang L; Liu J; Dai X; Shi J; Xie T; Dong J
J Neurooncol; 2018 Nov; 140(2):199-208. PubMed ID: 29995176
[TBL] [Abstract] [Full Text] [Related]
8. Human Cytomegalovirus (HCMV) infection was not correlated with overall survival in glioblastomas.
Han S; Wang PF; Xing YX; Song HW; Yao K; Lin ZX
Neoplasma; 2018 Mar; 65(3):431-435. PubMed ID: 29788727
[TBL] [Abstract] [Full Text] [Related]
9. Activated MEK cooperates with Cdkn2a and pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract] [Full Text] [Related]
10. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB; Xu J; Skanderup AJ; Dong Y; Brannon AR; Wang L; Won HH; Wang PI; Nanjangud GJ; Jungbluth AA; Li W; Ojeda V; Hakimi AA; Voss MH; Schultz N; Motzer RJ; Russo P; Cheng EH; Giancotti FG; Lee W; Berger MF; Tickoo SK; Reuter VE; Hsieh JJ
Nat Commun; 2016 Oct; 7():13131. PubMed ID: 27713405
[TBL] [Abstract] [Full Text] [Related]
11. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and pten: new opportunities for selected targeted therapies.
Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
[TBL] [Abstract] [Full Text] [Related]
12. High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma.
Meng D; Chen Y; Yun D; Zhao Y; Wang J; Xu T; Li X; Wang Y; Yuan L; Sun R; Song X; Huai C; Hu L; Yang S; Min T; Chen J; Chen H; Lu D
Oncotarget; 2015 Mar; 6(7):4901-19. PubMed ID: 25669971
[TBL] [Abstract] [Full Text] [Related]
13. Phase II study of PX-866 in recurrent glioblastoma.
Pitz MW; Eisenhauer EA; MacNeil MV; Thiessen B; Easaw JC; Macdonald DR; Eisenstat DD; Kakumanu AS; Salim M; Chalchal H; Squire J; Tsao MS; Kamel-Reid S; Banerji S; Tu D; Powers J; Hausman DF; Mason WP
Neuro Oncol; 2015 Sep; 17(9):1270-4. PubMed ID: 25605819
[TBL] [Abstract] [Full Text] [Related]
14. Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.
Conroy S; Kruyt FA; Joseph JV; Balasubramaniyan V; Bhat KP; Wagemakers M; Enting RH; Walenkamp AM; den Dunnen WF
PLoS One; 2014; 9(12):e115687. PubMed ID: 25546404
[TBL] [Abstract] [Full Text] [Related]
15. Expression and prognostic significance of TCTN1 in human glioblastoma.
Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
[TBL] [Abstract] [Full Text] [Related]
16. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract] [Full Text] [Related]
17. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
[TBL] [Abstract] [Full Text] [Related]
18. In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with pten as a key player.
Di Fiore R; Drago-Ferrante R; D'Anneo A; Augello G; Carlisi D; De Blasio A; Giuliano M; Tesoriere G; Vento R
Cancer Biol Ther; 2013 Oct; 14(10):922-31. PubMed ID: 23938948
[TBL] [Abstract] [Full Text] [Related]
19. pten promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract] [Full Text] [Related]
20. A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts.
Meyer S; Fuchs TJ; Bosserhoff AK; Hofstädter F; Pauer A; Roth V; Buhmann JM; Moll I; Anagnostou N; Brandner JM; Ikenberg K; Moch H; Landthaler M; Vogt T; Wild PJ
PLoS One; 2012; 7(6):e38222. PubMed ID: 22685558
[TBL] [Abstract] [Full Text] [Related]
[Next]
